|
| Home : The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1) |
|
Mar 24
2020 |
The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1) |
|
STOCKHOLM, March 24, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the publication of results from its O-12-M1 study, melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM), a multicenter, international, open-label, phase 1/2 study in... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/the-lancet-haematology-publishes-results-from-oncopeptides-multicenter-international-phase-12-study-o-12-m1-301028670.html |
| |
|
Related News
|
» OPERA 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Opera Limited - OPRA
» WATCH: Coronavirus daily update: March 23, 2020
|
|
|
